The effect of vitamin D in vitiligo patients

The effectiveness of vitamin D compared with placebo in vitiligo patients treated with Narrow Band UVB: A randomized control trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017031133014N1

Enrollment

Registered

2017-09-06

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: Pearl VIT D 50000 unit, Orally, on pearl every 2 weeks, for 2 months Plus Narrow Band UVB, 0.3 J / CM2. Intervention 2: Control group: Placebo, Orally, Every 2 week

Treatment - Drugs

Intervention group: Pearl VIT D 50000 unit, Orally, on pearl every 2 weeks, for 2 months Plus Narrow Band UVB, 0.3 J / CM2.

Control group: Placebo, Orally, Every 2 weeks a number for 2 months Plus Narrow Band UVB, 0.3 J / CM2.

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with generalized vitiligo or skin lesions equal or more than five percent of the body surface. Exclusion criteria: patients with hemodialysis and renal failure; receiving thiazide diuretics, lithium utilization; get systemic treatment in the last month; increasing serum leading to drug toxicity; age under 6 years old; phototherapy sessions less than 2 times a week.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Changes in the extent of skin involvement. Timepoint: Every 2 months until 4 months. Method of measurement: Based on Vitiligo Area Scoring Index (VASI) Score. In this method body is divided into five separate regions: the hands, upper extremities, trunk,lower extremities and feet. The face and neck areas are assessed separately. One hand unit of the patient (the palm plus the volar surface of the digits) is used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. For each body region, VASI is determined as the product of the vitiligo area in hand units (set at 1% per unit) and the pattern of depigmentation within each hand-unit-measured patch (possible values of 10, 25,50, 75, 90 or 100%, which are illustrated with a descrip-tive atlas of patient photographs). VASI, applied to the whole body, will calculated using the following formula, (possible range 0–100): all body sites (hand units) × depigmentation.	—

Measure

Time frame

Changes in the extent of skin involvement. Timepoint: Every 2 months until 4 months. Method of measurement: Based on Vitiligo Area Scoring Index (VASI) Score. In this method body is divided into five separate regions: the hands, upper extremities, trunk,lower extremities and feet. The face and neck areas are assessed separately. One hand unit of the patient (the palm plus the volar surface of the digits) is used as a guide to estimate the baseline percentage of vitiligo involvement of each body region. For each body region, VASI is determined as the product of the vitiligo area in hand units (set at 1% per unit) and the pattern of depigmentation within each hand-unit-measured patch (possible values of 10, 25,50, 75, 90 or 100%, which are illustrated with a descrip-tive atlas of patient photographs). VASI, applied to the whole body, will calculated using the following formula, (possible range 0–100): all body sites (hand units) × depigmentation.

—

Secondary

Measure	Time frame
Serum 25-hydroxyvitamin D level. Timepoint: At the beginning and at the 11th week of the study. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra ALsadat Mousavi

Skin Ward, Ahvaz Imam Khomeini Hospital

nafmousavi@gmail.commousavi.z@ajums.ac.ir+98 21 2245 6080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026